A detailed history of Vitruvian Partners LLP transactions in Maxcyte, Inc. stock. As of the latest transaction made, Vitruvian Partners LLP holds 5,043,356 shares of MXCT stock, worth $20.7 Million. This represents 7.62% of its overall portfolio holdings.

Number of Shares
5,043,356
Previous 5,043,356 -0.0%
Holding current value
$20.7 Million
Previous $19.8 Million 0.76%
% of portfolio
7.62%
Previous 5.8%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 14, 2022

BUY
$3.59 - $6.81 $2.36 Million - $4.48 Million
657,686 Added 15.0%
5,043,356 $23.9 Million
Q1 2022

May 04, 2022

BUY
$5.26 - $10.84 $5.55 Million - $11.4 Million
1,055,670 Added 31.7%
4,385,670 $30.7 Million
Q3 2021

Nov 15, 2021

BUY
$12.21 - $17.2 $40.7 Million - $57.3 Million
3,330,000 New
3,330,000 $40.7 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $418M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Vitruvian Partners LLP Portfolio

Follow Vitruvian Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vitruvian Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Vitruvian Partners LLP with notifications on news.